Skip to content

Unlock More Predictive Safety Research With Ncardia at SPS 2025

Oct 13-15, 2025
Jaarbeurs Utrecht, Netherlands
Booth: 201

Connect with Ncardia at the Safety Pharmacology Society (SPS) Annual Meeting to meet the solution that’s reshaping predictive toxicology and preclinical safety testing: iPSC-based platforms. Our high-throughput, human-relevant models are built to meet the rigorous demands of cardiac, neurological, and stem cell research offering the precision and scalability required for modern safety pharmacology. 

Let’s meet at SPS 2025 to discuss how our discovery services and iPSC-derived models can support your next study from early screening to regulatory submission. 

Presentation:
“Development and Characterization of Non-Human Primate iPSC-Derived Ventricular Cardiomyocytes for High-Throughput Safety Pharmacology Screening  
Speaker: Ilse Veldkamp-Baak MS, Scientist
Date: October 13th, 3-5 p.m.

Poster: #062
October 14th, 2-3 p.m.
October 15th, 11:10 a.m – 12:10 p.m.

Presentation:
“A Human iPSC-Based Platform for Functional Toxicity Screening of CNS-Targeted RNA Therapeutics” 
Speaker: Shushant Jain, PhD, Director of Discovery Technology
Date: October 14th, 3-5 p.m.

Poster Only: “A Physiologically Relevant 3D iPSC-Based Cardiac Microtissue Model for High-Throughput Screening" 

 

ABOUT US
Predict future safety and efficacy more efficiently

For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.

Learn more about SPS 2025!

Schedule a meeting by filling out the form below: